Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mesoblast Ltd (NASDAQ:MESO)

6.41
Delayed Data
As of Feb 17
 +0.0888 / +1.40%
Today’s Change
3.50
Today|||52-Week Range
10.89
+19.81%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$510.5M

Company Description

Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products. Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Contact Information

Mesoblast Ltd.
Level 38
Melbourne Victoria (vic) 3000
P:(139) 639-6036
Investor Relations:
(212) 880-2060

Employees

Shareholders

Mutual fund holders2.49%
Other institutional0.59%
Individual stakeholders--

Top Executives

Silviu ItescuChief Executive Officer, MD & Executive Director
Paul HodgkinsonChief Financial Officer
Donna L. SkerrettChief Medical Officer
Michael SchusterHead-Pharma Partnering
Jonathan Richard SymondsHead-Corporate Finance & Strategy